Marjan Asadi

Marjan Asadi

Auto-generated profile, based on publicly available information

Marjan Asadi

Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2025 in Biomarker Research
Verified
Journal Article
Open access
PDF file
DBDavood Bashash
Davood Bashash
HSHamed soleimani samarkhazan
Hamed soleimani samarkhazan
MAMarjan Asadi
Marjan Asadi
MZMitra Zabihi
Mitra Zabihi
SPSahar Parkhideh
Sahar Parkhideh
MMmohammad hossein Mohammadi
mohammad hossein Mohammadi
Acute myeloid leukemia (AML) with KMT2A rearrangements (KMT2A-r) represents a highly aggressive and prognostically unfavorable subtype of leukemia, often resistant to standard treatments and associated with high relapse rates. KMT2A-r, found in 3–10% of adult AML cases, disrupt epigenetic regulation by forming chimeric proteins that activate oncogenic pathways like HOXA and MEIS1. These fusion proteins recruit cofactors such as Menin and DOT1L, driving leukemogenesis through abnormal histone methylation. Diagnosing KMT2A-r AML requires precision, with traditional methods like FISH and RT-PCR being complemented by advanced technologies such as next-generation sequencing (NGS) and machine learning (ML). ML models, leveraging transcriptomic data, can predict KMT2A-r and identify biomarkers like LAMP5 and SKIDA1, improving risk stratification. Therapeutically, there is a shift from chemotherapy to targeted therapies. Menin inhibitors (e.g., Revumenib, Ziftomenib) disrupt the Menin-KMT2A interaction, suppressing HOXA/MEIS1 and promoting differentiation. DOT1L inhibitors (e.g., Pinometostat) show promise in combination therapies, while novel approaches like WDR5 inhibitors and PROTAC-mediated degradation are expanding treatment options. Despite progress, challenges remain, including optimizing minimal residual disease monitoring, overcoming resistance, and validating biomarkers. This review emphasizes the imperative to translate molecular insights into personalized therapeutic regimens, offering renewed hope for patients afflicted by this historically refractory malignancy.

9 May 2025 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
OAOmolbanin Sargazi Aval
Omolbanin Sargazi Aval
AAAli Ahmadi
Ali Ahmadi
AAAli Jihad Hemid Al-Athari
Ali Jihad Hemid Al-Athari
HSHamed soleimani samarkhazan
Hamed soleimani samarkhazan
FCFatemeh Sotudeh Chafi
Fatemeh Sotudeh Chafi
MAMojtaba Aghaei
Mojtaba Aghaei
Acute Myeloid Leukemia (AML) presents a formidable challenge in the realm of hematologic malignancies, characterized by the unregulated proliferation of myeloid progenitor cells, leading to severe disruptions in normal hematopoiesis. This review examines the multifaceted role of Galectin-9, a crucial glycan-binding protein in the pathophysiology of AML, emphasizing its potential as both a prognostic biomarker and a therapeutic target. Recent insights into the molecular underpinnings of AML, particularly those involving genetic mutations and cytogenetic abnormalities, illuminate the complex landscape of this disease, where patient outcomes are significantly influenced by individual biological markers. Galectin-9, initially recognized for its involvement in fundamental biological processes such as cell proliferation and immune modulation, has emerged as a pivotal molecule in AML, with expression levels correlating with leukemic cell behavior and clinical prognosis. This review consolidates the extensive literature on Galectin-9, elucidating its role in leukemic transformation and the therapeutic implications of manipulating this pathway. By investigating the intricate relationship between Galectin-9 and AML, we aim to provide a comprehensive understanding that could lead to innovative strategies for managing this aggressive malignancy, offering hope for improved survival outcomes through targeted therapeutic interventions.

29 June 2026 in International Journal of Cancer Management
Verified
Journal Article
Open access
PDF file
SYSamareh Younesian
Samareh Younesian
SPSayeh Parkhideh
Sayeh Parkhideh
SPSahar Parkhideh
Sahar Parkhideh
SSSahar Tavakkoli Shiraji
Sahar Tavakkoli Shiraji
OYOmmolbanin Younesian
Ommolbanin Younesian
DBDavood Bashash
Davood Bashash
Background: Albumin and the albumin-to-globulin ratio (AGR) are established prognostic markers in multiple myeloma (MM); however, the prognostic value of baseline serum total protein in patients with MM undergoing autologous stem cell transplantation (ASCT) remains unclear. Objectives: This study investigated the prognostic significance of baseline total protein for progression-free survival (PFS) in patients with MM undergoing autologous stem cell transplantation (ASCT). Methods: Twenty-one consecutive patients with MM who underwent ASCT between 2023 and 2025 at the Stem Cell Transplant Research Center of Taleghani Hospital were included. Survival outcomes were evaluated using Kaplan-Meier estimates stratified by baseline total protein levels and Cox proportional hazards models. Patients were followed for a median of 19 months (range, 10.5 - 32 months). Results: Higher baseline total protein was significantly associated with inferior PFS (HR, 2.10; 95% CI, 1.08 - 4.08; P = 0.028). Patients with total protein > 9 g/dL had significantly shorter PFS and 12-month PFS than those with total protein ≤ 9 g/dL (log-rank test; P = 0.008 and P = 0.029, respectively). A trend toward inferior OS was observed (log-rank test; P = 0.052). Elevated total protein was strongly correlated with M-protein and globulin levels and was associated with lower hemoglobin levels and a higher erythrocyte sedimentation rate (ESR). Conclusions: Higher baseline total protein is associated with inferior PFS in patients with MM undergoing ASCT. Given its simplicity and universal availability, it may serve as a cost-effective and accessible prognostic marker at the time of diagnosis. Larger prospective studies are needed to validate its independent prognostic value.